Recently, in the EMPA-REG OUTCOME trial, the SGLT2 inhibitor empagliflozin significantly reduced the rate of primary composite cardiovascular outcome and death from any cause in patients with type 2 diabetes at high cardiovascular risk [10]. Here, SLC5A2 is linked to type 2 diabetes mellitus.